(Total Views: 782)
Posted On: 11/21/2024 4:06:57 PM
Post# of 154730
A couple of comments after attending the RECOVER TLC meeting today:
1) Broadly the data is telling us there are three mechanisms in the pathogenesis of long covid: viral reactivation, viral persistence, and immune deregulation.
2) 72% of the submissions were from patients! Underscores those suffering are pressing for solutions.
3) Nearly 70% of the submissions were for drug interventions…they showed a list of specific agents and some as categories like COVID MABS…Leronlimab was not specifically listed and it would be improper to throw it into the COVID MAB bucket by my definition. The list of drugs had counts and appeared to include 4 or more mentions.
4) I am a little surprised Leronlimab was not mentioned…when I filed I listed its mechanism under the immune modulation category.
5) The portal is still open for submission. Not sure if it matters to boost the Leronlimab rating, Dr Jay has been talking with the NIH for years, and I find it hard to believe it is not on their radar. Still, not 4 submissions?! Or, they dumped it under the MAB’s.
6) Jeanne Marrazzo stressed the need both for specific bio markers and an emphasis on agents that are ready for phase 2/3. They are also collaborating with EMA as they want to get something helpful into the market and an agent that can quickly spill over into Europe as well.
By Jeanne’s litmus test Leronlimab would certainly qualify…completed phase 2 study with a very provocative finding involving immune modulation.
1) Broadly the data is telling us there are three mechanisms in the pathogenesis of long covid: viral reactivation, viral persistence, and immune deregulation.
2) 72% of the submissions were from patients! Underscores those suffering are pressing for solutions.
3) Nearly 70% of the submissions were for drug interventions…they showed a list of specific agents and some as categories like COVID MABS…Leronlimab was not specifically listed and it would be improper to throw it into the COVID MAB bucket by my definition. The list of drugs had counts and appeared to include 4 or more mentions.
4) I am a little surprised Leronlimab was not mentioned…when I filed I listed its mechanism under the immune modulation category.
5) The portal is still open for submission. Not sure if it matters to boost the Leronlimab rating, Dr Jay has been talking with the NIH for years, and I find it hard to believe it is not on their radar. Still, not 4 submissions?! Or, they dumped it under the MAB’s.
6) Jeanne Marrazzo stressed the need both for specific bio markers and an emphasis on agents that are ready for phase 2/3. They are also collaborating with EMA as they want to get something helpful into the market and an agent that can quickly spill over into Europe as well.
By Jeanne’s litmus test Leronlimab would certainly qualify…completed phase 2 study with a very provocative finding involving immune modulation.
(24)
(0)
